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A country-wide sentinel surveillance system was initiated in Germany after 
implementation of routine varicella vaccination of children >11 months. Sentinel 
physicians report monthly the number of cases and of severe varicella complications 
(VC). Case-based questionnaires are completed for VC. We evaluated trend and 
clinical features of reported VC from April 2005 to March 2009. Reported VC 



































































   
 3 
Introduction 
Although varicella is commonly regarded as a mild disease, serious complications 
and death occur (2). In Germany, up to June 2004 vaccination against varicella was 
only recommended for special risk groups and their contacts and as post-exposure 
prophylaxis. Universal varicella vaccination of all children 11-14 months of age was 
recommended by Germany’s Standing Committee on Vaccination in July 2004 (6).  
The main objective of this recommendation was reduction of morbidity,and varicella 
complications and consequently, the economic burden of disease (5). Varicella is not 
notifiable in Germany. Countrywide varicella sentinel surveillance was initiated1 in 
April 2005 to evaluate the effects of vaccination. Operative details of the sentinel 
system have been described elsewhere (7).  
This report describes frequency and type of severe varicella complications (VC) 
found in four years of sentinel surveillance.  
 
Methods 
The sentinel consists of a countrywide convenience sample of more than 1,000 
primary care physicians, of whom 60% are paediatricians and 40% general 
practitioners (GP). The relative geographic distribution of the sentinel physicians is 
comparable to the total number of active physicians (~1% of GPs and ~15% of all 
paediatricians in each region). Participation is voluntary, no incentives are given. 
Monthly questionnaires are actively requested and contain aggregated numbers 
(including zero) of varicella cases by age group and on patients with VC. Additional 
case based reports for all patients with VC contain information on age, sex, 




































































   
 4 
Questionnaires include case definitions: A case of varicella is defined as a person 
presenting with a typical clinical picture of maculo-papulo-vesicular rash on skin or 
mucosa. A severe varicella complication (VC) is defined as varicella leading to 
hospitalization, resulting in oral or parenteral antibiotic or antiviral therapy or 
accompanied by neurologic symptoms. We analyzed the frequency and type of VC 
within the sentinel system in four consecutive seasons (April until March of the 
following year).  
For data entry and management MS Access 2007© was used, MS Excel 2007© and 
Stata® version 10 (StataCorp LP, Texas, USA) were used for data analysis. 
Consistency checks were performed by comparing single case reporting of VC via 
case-based questionnaire with the total number of VC cases reported via monthly 
questionnaire. Using Pearson chi-squared test statistically significant differences 
were determined. All p-values are two-sided and the significance level set at p<0.05.  
 
Results: 
From April 2005 to March 2009, 83,075 varicella cases were reported in monthly 
questionnaires by 1,176 sentinel physicians. While participation of sentinel 
physicians remained stable, the number of reported varicella cases as well as of VC 
decreased by 63% and 81%, respectively, when comparing the 4th to the 1st season. 
Cases of varicella and VC peaked in spring.  
Overall, 280 VC were reported via case-based questionnaires (10% less than in the 
monthly figures) by 150 physicians, corresponding to 0.34% of all reported varicella 


































































   
 5 
Most VC occurred in 0-4 (59%) and 5-9 (31%) year olds, 126 (48%) in males. Of all 
reported varicella cases the highest proportion of complications occurred in children 
younger than 2 (24%) and adults older than 20 (5%) years old.  
The type of complication could be identified in 278 VC patients: 144 dermatologic, 27 
neurologic and 127 other complications (Table 1). Twenty VC patients had more than 
one type of complication. Bacterial superinfections (n=108, 36% of VC and 0.13% of 
all reported varicella cases, respectively) were most common among skin 
complications, followed by phlegmon (spreading diffuse inflammatory process with 
formation of pus, n=15, 5% of VC) and abscess (localized, cavity formed and 
drainable infected fluid collection, n=9, 3% of VC). Among “other complication” 47 
cases had otitis media (16% of VC and 0.06% of all varicella cases, respectively) and 
21 had pneumonia (7% of all VC). Neurologic complications accounted for 0.03% of 
all varicella cases (n=27, 9% of all VC). A decline in the number of complications 
over time was observed in all 3 reported categories, but was greatest for skin and for 
other complications.  
Underlying conditions were reported in 30 (11%) VC cases, in three more than one 
condition was present: Twelve patients had atopic dermatitis, 11 had chronic 
diseases such as bronchial asthma, diabetes mellitus, dismorphic syndrome with 
retarded growth, coronary fistula, multifocal pneumonia with residual bronchitis, 
nephrocalcinosis, valvular and aortal stenosis, epilepsy and anemia. Six patients had 
underlying immune-compromising conditions and four were oncology patients. The 
type of VC did not differ between previously healthy and patients with underlying 
conditions, but the latter were hospitalised more often (34.0% vs. 27.0%) and 


































































   
 6 
Seventy-one VC cases were hospitalised (median age 3 years). Patients with 
neurologic VC were hospitalized more often than patients with dermatologic or other 
VC (56% vs. 21% and 24%, respectively).  
In 94 cases (33%) the outcome remained unknown, 165 (59%) recovered 
completely, 19 (7%) developed permanent sequelae and two patients died 
Comparison of those having permanent sequalae or death (n=21) with those who 
fully recovered (n=165) showed no significant difference by gender, age-groups, 
complications type and vaccination status. 
Of 277 VC with known vaccination status 16 (5.8%) were vaccinated, none of them 
twice. In six cases varicella presented within 42 days after vaccination, suggesting 
vaccination within the incubation period or vaccine related varicella. Ten cases 
occurred more than 42 days after vaccination (breakthrough cases): five presented 
with otitis media (one combined with bronchitis and one with balanitis) and two with 
bacterial superinfection. Three patients had other complications, two of whom were 
hospitalized because of dehydratation and nephrotic syndrome. 
 
Discussion 
Our results give the first assessment of severe varicella complications after the 
introduction of universal varicella vaccination in Germany. Studies estimating the 
burden of VC before introduction of universal childhood varicella vaccination have 
relied mostly on hospital data (1;4;8;9).  
Our findings are are similar to those of Ziebold et al. (9), who demonstrated in a one 
year survey of children younger than 16 years within pediatric hospitals in Germany 
that the majority of complications occurred in pre-school aged children, especially in 
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Among hospitalized VC patients reported, the median age was comparable to that 
estimated by capture-recapture analysis by Liese et al. (3;4) before universal 
varicella vaccination was available in Germany. In this study, an underlying chronic 
disease was reported in 23% of hospitalized cases, in contrast to 14% among the 
hospitalized cases reported in the sentinel. However, in both studies the majority of 
patients with VC or who were hospitalized related to VC were previously healthy 
persons. This supports the general recommendation for varicella vaccination in 
childhood rather than a vaccination targeted only at risk groups.  
Within the sentinel, the proportion of VC was smaller than estimated by Wutzler et al. 
(8) in a combined seroepidemiologic and analytic study. Possibly our results do not 
reflect the true proportion because very severe cases present directly at the hospital 
and are not retrospectively reported by the sentinel physician. Furthermore, 
physician-based surveillance is known to be affected by reporting bias, possibly 
leading to underreporting.  
The total number of varicella cases and reported complications within the sentinel 
decreased over time with increasing vaccine uptake (11). The overall numebr of VC 
is low, confirming the success of the varicella vaccination program in Germany. Long 
term consequences of routine varicella vaccination cannot be determined with the 
use of our sentinel data. Population based surveillance programs should be 
established in the future to monitor further the impact of varicella vaccination on the 
epidemiology of varicella infections. 
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Figure 1: Proportion of varicella complications among all varicella cases reported 
within the varicella sentinel surveillance system in Germany, 2005-2009 
 
Figure 2: Decrease of varicella complications within the varicella sentinel surveillance 
system in Germany, 2005-2009 
 
Figure 3: Varicella complications by age-groups and by gender within the varicella 
sentinel surveillance system in Germany, 2005-2009 
 
Figure 4: Proportion of varicella complications among all varicella cases reported by 




Table 1: Varicella complications by type, underlying conditions and hospitalisation 























skin  144 48.3  126 47.2 18 58.1 30 
bacterial 
superinfections 
104 34.9 3.5 90  12  18 
phlegmona 13 4.4 4 11  2  5 
abscess 7 2.3 2 6  1  2 
superinf. with 
phlegmona 
2 0.7 5 2  0  0 
superinf. with 
abscess 
2 0.7 3 2  0  0 
*other skin infection 16 5.4 3 13  3  5 
neurological 27 9.1  27 10.1 0 0 15 
cerebellitis 7 2.3 5 7  0  4 
encephalitis 6 2.0 5 6  0  4 
meningitis 1 0.3 0 1  0  1 
§other neurol. compl. 13 4.4 5 13  0  6 
other 
complications 
127 42.6  114 42.7 13 41.9 31 
otitis media 47 15.8 4 46  1  2 
pneumonia 20 6.7 4 17  3  7 
arthritis 5 1.7 3 4  1  1 
hemato-oncologic 
sympt. 




1 0.3 20 1  0  1 
$further VC 50 16.8 4 42  8  16 
#multiple nominations * conjunctivitis, blepharitis, erysipel, impetigo etc. § facial paresis, 
tinnitus, hyperreflexia etc. $ lymphadenitis, keratinitis etc. 
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